ArticleScientific reports2026
Establishment of a prognostic model for hepatocellular carcinoma patients based on bioinformatics analysis and exploration of prognostic biomarker EPPK1.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) poses a significant global health challenge, and its complex and diverse pathogenesis requires further in-depth investigation. With the development of bioinformatics, omics sequencing has become an indispensable detection tool for dissecting the complex molecular characteristics of diseases. We analyzed the transcriptomic and proteomic data from TCGA-LIHC and identified a prognosis-related gene, EPPK1. Subsequently, validation by single-cell sequencing revealed that EPPK1 is specifically highly expressed in HCC cells. Further combined analysis of immune infiltration and spatial transcriptomics indicated that high EPPK1 expression is associated with various immune cells, particularly showing a negative correlation with CD8 + T cells. Enrichment analysis of EPPK1-related transcriptomic data demonstrated that EPPK1 is involved in pathways such as cell cycle and apoptosis of HCC. We employed virtual perturbation technology to predict the potential downstream pathways associated with EPPK1. Finally, in vitro functional experiments confirmed that EPPK1 promotes the malignant progression of HCC cells. Our study suggests that EPPK1 is a promising diagnostic and prognostic biomarker in HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.